Engineered “stealth” immune cells from MIT and Harvard show promise for fast, safe, and powerful cancer treatment. Scientists have created a new and more advanced form of immune-based cancer therapy using engineered cells known as CAR-NK (natural killer) cells. Like CAR-T cells, these modified immune cells can be programmed to recognize and attack cancer, but they rely on a different type of immune cell that naturally targets abnormal or infected cells.

A team from MIT and Harvard Medical School has now developed a more effective way to engineer CAR-NK cells that dramatically reduces the chance of the body’s immune system rejecting them. Immune rejection has been one of the biggest limitations of cell-based therapies, often weakening their effectiveness.

This innovation could also make it possible to produce “off-the-shelf” CAR-NK treatments that are available immediately after diagnosis, rather than waiting weeks for custom-engineered cells. Traditional CAR-NK and CAR-T manufacturing methods typically require several weeks to complete before patients can begin treatment.